Aeglea BioTherapeutics is headquartered at 805 Las Cimas Parkway, Suite 100, Austin, TX 78746.
Aeglea BioTherapeutics is incorporated in the state of Delaware.
Aeglea BioTherapeutics will end the fiscal year on December 31st.
Aeglea BioTherapeutics trades on the NASDAQ Global Market under the symbol “AGLE”.
Aeglea BioTherapeutics’ transfer agent is American Stock Transfer & Trust Company, LLC.
American Stock Transfer & Trust Company (800) 937-5449 (Toll-free) (718) 921-8124 (International) http://www.amstock.com/new/InvestorServices/ShareholderServices.aspx
If delivering by mail:
American Stock Transfer & Trust Company Operations Center Attn: Reorganization Department P.O. Box 2042 New York, NY 10272-2042
If delivering by hand or courier:
American Stock Transfer & Trust Company Operations Center Attn: Reorganization Department 6201 15th Avenue Brooklyn, NY 11219
Aeglea BioTherapeutics’s auditor is PricewaterhouseCoopers LLP, Austin, Texas.
Aeglea BioTherapeutics SEC filings can be viewed on our SEC Filings page.
You can submit queries to Aeglea BioTherapeutics investor relations department by contacting investors@aeglea.com.